Urinary Titin Biomarker in DMD
NCT07332013
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A universal challenge in clinical investigation of novel therapeutics is the need for quantitative, objective biomarkers that directly address the mechanisms of disease and provide information relevant to clinically meaningful functional improvement. This has been a particular challenge in rare and slowly progressive diseases such as Duchenne Muscular Dystrophy (DMD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Duchenne Muscular Dystrophy (DMD)
- Becker's Muscular Dystrophy (BMD)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 2 to 10 years
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- Children's Hospital of Philadelphia
- Last updated on ClinicalTrials.gov
- April 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- Children's Hospital of Philadelphia · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.